Freed versus Augmedix market split

The Augmedix comp shows how much value the market used to assign to AI scribing when it looked more like a services heavy hospital vendor than a software scale story. Augmedix reached $45M of 2023 revenue with roughly 1,500 clinicians in service by mid 2023, but it sold mainly to large health systems through slower enterprise workflows, and Commure bought it to plug ambient documentation into a broader hospital software bundle, not as a standalone breakout asset.

• Augmedix and Freed solve the same core problem, turning visits into notes, but with very different economics. Freed reached $13M ARR on about 12,000 clinicians at roughly $1K ACV, while Augmedix did $45M in 2023 through a much higher touch model tied to enterprise deployments and deeper service overhead.
  1 sacra 2 sacra 4 sacra 5 augmedix
• The buyer context is different. Freed can win when one doctor or a five doctor clinic swipes a card and starts using the product. Once a scribe sale touches larger practices or hospitals, HIPAA reviews, BAAs, IT signoff, and EHR integration turn it into a standard enterprise sale. That is the lane Augmedix lived in.
  2 sacra 3 sacra 5 augmedix
• The Commure deal explains the 3x multiple. Commure was assembling an all in one hospital stack across billing, monitoring, workflows, and clinician tools, and Augmedix added ambient documentation plus health system relationships. In that setup, Augmedix was more valuable as a cross sell module inside a platform than as a public pure play scribe company.
  3 sacra 4 sacra 6 cloudfront

Going forward, the market is likely to split in two. Bottom up products like Freed can compound fast by owning the long tail of small practices with cheap self serve software. Enterprise scribes will keep consolidating into larger healthcare platforms, where the upside comes from bundling documentation with coding, billing, and workflow automation across hospital systems.